TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2019

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.

James Chih-Hsin Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.